News | August 12, 2022
Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.
The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly)
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
The company has responded to the warning letter and carried out the committed corrections.
Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.
Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
Subscribe To Our Newsletter & Stay Updated
